En Es
Categories

QUOTIENT DIAGNOSTICS

QUOTIENT DIAGNOSTICS

Quotient is a commercial-stage diagnostics company that develops and manufactures products for use in transfusion diagnostics. It offers a next-generation automation platform for both blood grouping and donor disease screening, products for blood grouping, and whole blood controls for quality assurance testing of third-part ...
Products Covid-19Summary
Close

Covid-19 QUOTIENT DIAGNOSTICS

Clinical Laboratory

Blood Testing Platform
MosaiQ

The MosaiQ is the world’s first fully-automated testing solution that will allow for rapid, extensive antigen typing/antibody identification of donor and patient blood utilizing a single Microarray (or consumable). It enables workflow efficiencies through walk-away-capable processing of approximately 1,000 samples in a single 8-hour shift. The MosaiQ COVID-19 Antibody Microarray combines with the multiplexing, high-throughput MosaiQ instrument to quickly and accurately evaluate samples in central laboratories.
More details

COVID-19 IgM/IgG Antibody Test
MosaiQ COVID-19 Antibody Microarray

The MosaiQ COVID-19 Antibody Microarray tests for both IgM and IgG antibodies to SARS-CoV-2, the virus that causes COVID-19, offering one of the earliest antibody detection tests available. Independent and internal studies have confirmed best-in-class performance with 100% sensitivity and 99.8% specificity. It can detect seroconversion as early as 24 hours post PCR and detects antibodies as early as 7 days post PCR. The innovative technology that allowed Quotient to create the MosaiQ COVID-19 Antibody Microarray is powered by the proprietary MosaiQ Reaction that delivers fast, accurate results every 24 seconds on the MosaiQ system – a multiplexing, multimodal solution for central laboratories. The best-in-class MosaiQ COVID-19 Antibody Microarray is CE marked, has received the U.S. FDA Emergency Use Authorization (EUA).
More details
Close

About QUOTIENT DIAGNOSTICS

Quotient is a commercial-stage diagnostics company that develops and manufactures products for use in transfusion diagnostics. It offers a next-generation automation platform for both blood grouping and donor disease screening, products for blood grouping, and whole blood controls for quality assurance testing of third-party blood grouping instruments.

Recently updated

COVID-19 IgM/IgG Antibody Test
MosaiQ COVID-19 Antibody Microarray

The MosaiQ COVID-19 Antibody Microarray tests for both IgM and IgG antibodies to SARS-CoV-2, the virus that causes COVID-19, offering one of the earliest antibody detection tests available. Independent and internal studies have confirmed best-in-class performance with 100% sensitivity and 99.8% specificity. It can detect seroconversion as early as 24 hours post PCR and detects antibodies as early as 7 days post PCR. The innovative technology that allowed Quotient to create the MosaiQ COVID-19 Antibody Microarray is powered by the proprietary MosaiQ Reaction that delivers fast, accurate results every 24 seconds on the MosaiQ system – a multiplexing, multimodal solution for central laboratories. The best-in-class MosaiQ COVID-19 Antibody Microarray is CE marked, has received the U.S. FDA Emergency Use Authorization (EUA).
More details

Antiglobulin Tests Sensitivity Control
ALBAcheck-BGS AlbaSure Sensitivity Control Kit

The ALBAcheck-BGS AlbaSure Sensitivity Control Kit is intended for use as a sensitivity control of antiglobulin tests. The kit Anti-K, Anti-c and Anti-E have been prepared from plasma collected from blood donors. Each individual donation contains IgG antibodies of the required specificity.
More details

RhD Variant Investigation Kit
ALBAclone RhD Variant Investigation Kit

The ALBAclone RhD Variant Investigation Kit is intended for the in vitro investigation of human RhD variants by indirect and direct agglutination. When used by the recommended techniques, each Anti-D sera in the kit will cause agglutination (clumping) of red blood cells expressing the antigen (D epitope(s)) to which each Anti-D is directed. Lack of agglutination means that the antigen (epitope) to which each antibody is directed is not present. The probable RhD variant will be indicated by review of the pattern of reactivity obtained when testing red blood cell sample with all 12 antibodies.
More details

Clinical Laboratory

COVID-19 IgM/IgG Antibody Test
MosaiQ COVID-19 Antibody Microarray

The MosaiQ COVID-19 Antibody Microarray tests for both IgM and IgG antibodies to SARS-CoV-2, the virus that causes COVID-19, offering one of the earliest antibody detection tests available. Independent and internal studies have confirmed best-in-class performance with 100% sensitivity and 99.8% specificity. It can detect seroconversion as early as 24 hours post PCR and detects antibodies as early as 7 days post PCR. The innovative technology that allowed Quotient to create the MosaiQ COVID-19 Antibody Microarray is powered by the proprietary MosaiQ Reaction that delivers fast, accurate results every 24 seconds on the MosaiQ system – a multiplexing, multimodal solution for central laboratories. The best-in-class MosaiQ COVID-19 Antibody Microarray is CE marked, has received the U.S. FDA Emergency Use Authorization (EUA).
More details

Antiglobulin Tests Sensitivity Control
ALBAcheck-BGS AlbaSure Sensitivity Control Kit

The ALBAcheck-BGS AlbaSure Sensitivity Control Kit is intended for use as a sensitivity control of antiglobulin tests. The kit Anti-K, Anti-c and Anti-E have been prepared from plasma collected from blood donors. Each individual donation contains IgG antibodies of the required specificity.
More details

RhD Variant Investigation Kit
ALBAclone RhD Variant Investigation Kit

The ALBAclone RhD Variant Investigation Kit is intended for the in vitro investigation of human RhD variants by indirect and direct agglutination. When used by the recommended techniques, each Anti-D sera in the kit will cause agglutination (clumping) of red blood cells expressing the antigen (D epitope(s)) to which each Anti-D is directed. Lack of agglutination means that the antigen (epitope) to which each antibody is directed is not present. The probable RhD variant will be indicated by review of the pattern of reactivity obtained when testing red blood cell sample with all 12 antibodies.
More details

Blood Testing Platform
MosaiQ

The MosaiQ is the world’s first fully-automated testing solution that will allow for rapid, extensive antigen typing/antibody identification of donor and patient blood utilizing a single Microarray (or consumable). It enables workflow efficiencies through walk-away-capable processing of approximately 1,000 samples in a single 8-hour shift. The MosaiQ COVID-19 Antibody Microarray combines with the multiplexing, high-throughput MosaiQ instrument to quickly and accurately evaluate samples in central laboratories.
More details

Sensitivity Control Kit
ALBAsure Kit

The ALBAcheck BGS AlbaSure Sensitivity Control Kit Anti-K, Anti-c and Anti-E are intended for use as a sensitivity control for antiglobulin tests. They have been prepared from plasma collected from blood donors with each individual donation containing IgG antibodies of the required specificity.
More details

Monoclonal Antisera
Anti-Fyb and Anti-Cw

The Anti-Fyb and Anti-Cw monoclonal antisera give robust reactions with significantly shorter incubation times, thus improving the technologist’s efficiency and confidence.
More details
Copyright © 2000-2021 TradeMed.com. All rights reserved. | Terms And Conditions